Financial results for FY2019 Q3 Financial Summary...2019/11/14 · Q3 FY2018 Q3 Jan.2018 –Sep. 2018 FY2019 Q3 Jan. 2019 –Sep 2019 YoY comparison Change Change rate Orders 9,368

Financial results for FY2019 Q3

Financial SummaryNov. 14, 2019

NIKKISO CO., LTD.Securities code: 6376

Disclaimer

This material contains forward-looking statements about future business performance. These statements by definition involve risks and uncertainties and are not intended to guarantee future performance. Actual results in the future may differ from the

estimates presented in the material herein due to changes in the business environment and other factors.

Copyright © 2019 NIKKISO CO., LTD. All rights reserved.

2

Ⅰ. Consolidated Performance

Appendix

Company Information

Ⅱ. Performance by Business Segment

Ⅲ. Financial forecast

2


Table of Contents

Ⅰ. Consolidated Performance

Copyright © 2019 NIKKISO CO., LTD. All rights reserved. 4

FY2018 Q3 Jan.2018 – Sep.2018

FY2019 Q3Jan.2019 – Sep.2019

YoY comparison

Change Change rate

Orders 122,745 126,325 +3,580 +2.9%

Revenue 115,437 121,193 +5,755 +5.0%

Operating profit 6,308 9,511 +3,203 +50.8%

Operating margin 5.5% 7.8%

Profit before tax 6,175 8,359 +2,183 +35.4%

Pretax profit margin 5.3% 6.9%

Profit for the yearattributable to owners of the company

4,296 4,638 +342 +8.0%

Profit marginattributable to owners of the company

3.7% 3.8%

Average foreign exchange rate

Against the US dollar (Yen) 109.60 109.12 △0.48 -

Against the euro (Yen) 130.87 122.62 △8.25 -


Consolidated Performance

Millions of JPY


FY2018 Q3

Jan.2018 – Sep. 2018

FY2019 Q3

Jan. 2019 – Sep. 2019Change Remarks

Gross profit 40,437 40,780 +343

- Selling, general and administrative expenses 34,536 33,109 △1,426

Decrease in SG&A expenses at overseassubsidiaries, exclusion of subsidiaries from consolidation (particle analytical equipment business), etc.

- Other income 493 4,127 +3,634

Gain on sales of the particle analytical equipment business (+2,416) and income from a joint venture agreement in the deep UV-LED business (income from a licensing agreement: +1,000)

- Other expenses 85 2,286 +2,201 Expenses related to the impairment of CRRT business assets (+2,149)

Operating profit 6,308 9,511 +3,203

- Financial income 524 434 △89

- Financial costs 829 1,436 +606 Increase in foreign exchange loss due tothe appreciation of the yen

- Share of profit of associates and joint ventures accounted for using the equity method

171 △150 △322 Share of loss of a joint venture company (deep UV-LED business)

Profit before tax 6,175 8,359 +2,183

Closing rate

- Against the US dollar (Yen) 113.57 107.92 △5.65

- Against the euro (Yen) 132.14 118.02 △14.12


Breakdown of Profit/Loss

Millions of JPY


FY2018 FY2019(forecast)


Quarterly results trend

Millions of JPY


1$ = 112.16Yen1€ = 126.70Yen


1$ = 110.44Yen1€ = 130.35Yen

FY2017

29,522

62,910

97,199

140,912

34,492

75,578

115,437

165,326

37,480

78,956

121,193

171,500

1,238

2,441

4,972

8,718

864

3,168

6,308

10,302

2,154

3,558

9,511

12,000

Revenue Operating profit

Q1 Q2 Q3 Q4 Q1 Q2 Q4 Q1 Q2 Q3 Q4


1$ = 109.00Yen1€ = 122.00Yen

Q3

Ⅱ. Performance by Business Segment



Performance by Business Segment

FY2018 Q3Jan.2018 - Sep.2018

FY2019 Q3Jan.2019 - Sep.2019

YoY comparison

Change Change rate

IndustrialBusiness

Orders 79,997 79,937 △60 △0.1%

Revenue 72,703 75,473 +2,770 +3.8%

Operating profit 5,682 8,03910.7%

+2,356 +41.5%

Operating margin 7.8%

Industrial DivisionOrders 58,634 59,550 +915 +1.6%

Revenue 53,337 54,285 +948 +1.8%

Precision Equipment Division

Orders 9,368 6,265 △3,103 △33.1%

Revenue 7,343 7,055 △287 △3.9%

Aerospace DivisionOrders 11,912 13,265 +1,352 +11.4%

Revenue 11,929 13,257 +1,327 +11.1%

MedicalBusiness

Orders 42,747 46,387 +3,640 +8.5%

Revenue 42,734 45,719 +2,984 +7.0%

Operating profit 3,233 1,7673.9%

△1,466 △45.3%

Operating margin 7.6%

Corporate expenses, etc. Operating profit △2,607 △294 +2,313 -

Millions of JPY


40%

6%14%

10%

25%

5%

9

FY2019Q3

FY2018 Q3Jan.2018 – Sep 2018

FY2019 Q3Jan. 2019 – Sep 2019

YoY comparison

Change Change rate

Orders 58,634 59,550 +915 +1.6%

Revenue 53,337 54,285 +948 +1.8%

Geveke


Industrial Division

1. Overview

2. Consolidated performance 3. Revenue Composition ratio by Product

Millions of JPY

Reciprocating pump

Canned motor pump

Cryogenics pump

CI Group

Others

✓ Continued capital investments in the upstream sector (e.g., oil and gas mining) and the downstream

sector (e.g., petrochemical). LEWA’s petrochemical pump sales (downstream sector) and after-sales

service business remained strong, achieving year-on-year increase of revenue and profit.

✓ Orders for large cryogenic pumps increased along with global market growth (e.g., an increase in

LNG-receiving terminals).

✓ Cryogenic Industries Group its revenue and profit increased year on year thanks to growing sales of

LNG-related products and decreased depreciation expenses.



Quarterly performance trend of LEWA

Millions of €

FY2019

Q1 Q4Q3Q2Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

FY2017 FY2018 2019計画

51

105

151

200

58

132

197

247

71

136

206

250

46

107

170

236

46

94

153

237

53

108

177

243

3 918

28

1 411

22

5 1226 30

125 119

101

84

106

133 138

95

115 123 125

-200

-150

-100

-50

0

50

100

150

0

50

100

150

200

250

300

350

百万

受注高（左軸）売上収益（左軸） EBITDA（左軸）受注残高（右軸）Reveue (Left axis)Order (Left axis) EBITDA (Left axis) Order backlog(Right axis)

(forecast)


194

54

87

137

212

51

96

140

198

31

65

92

124

28

67

113

162

43

87

127

188

4 9 11 141 5 11

175 9 11

22

116 114 108 111

138 146 147 150

-150

-100

-50

0

50

100

150

0

50

100

150

200

250

受注高（左軸）売上収益（左軸） EBITDA（左軸）受注残高（右軸）

11

Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

53%

33%

14%

44%

34%

21%Revenue Composition

ratio by segment

ACD

Cryoquip

Cosmodyne

47%

33%

20%

47%37%

16%

FY2019

Q3FY2018FY2017

FY2019

forecast

FY2017※unaudited FY2018 2019(forecast)


Quarterly performance trend of CI group

Order (Left axis) Reveue (Left axis) EBITDA (Left axis)Millions of ＄

Q1 Q4Q3Q2

FY2019

Order backlog(Right axis)


18%

32%40%

10%

12

FY2019Q3

FY2018 Q3Jan.2018 – Sep. 2018

FY2019 Q3Jan. 2019 – Sep 2019

YoY comparison

Change Change rate

Orders 9,368 6,265 △3,103 △33.1%

Revenue 7,343 7,055 △287 △3.9%



1. Overview


Millions of JPY

Power plant-related equipment

Particle analyzers

Electronic component manufacturing equipment Others

✓ Sales of power plant-related equipment remained weak due to soft domestic market conditions.

✓ Orders for electronic component manufacturing equipment decreased due to Apple’s shock

announcement and slowing capital investment caused by the U.S.–China trade friction, but both

manufacturing and shipments for existing orders were steady.

✓ On July 8, 2019, the particle analytical equipment business completed the transfer of shares.

Effective the 3rd quarter under review, this business is excluded from consolidation. As a result,

the Precision Equipment Business reported fewer orders and less sales revenue as a whole

compared with the same period last year.


43%

14%

25%

14%

4%

13

FY2018 Q3Jan.2018 – Sep. 2018

FY2019 Q3Jan. 2019 – Sep. 2019

YoY comparison

Change Change rate

Orders 11,912 13,265 +1,352 +11.4%

Revenue 11,929 13,257 +1,327 +11.1%

FY2019Q3


Aerospace Division


Millions of JPY Cascade

Nacelle parts

Wing parts

Jet engine parts

Others

1. Overview

✓ The number of inquiries that the Company received increased steadily as commercial aircraft demand

mainly for small planes (single-aisle planes) continuously increased primarily in Southeast Asia. No

major effects on the shipment of products for Boeing 737 MAX at present.

✓ Revenue increased year on year as the shipment of main products (cascades and engine parts) increased.

✓ Profit decreased due to increased expenses including depreciation expenses for the Miyazaki Factory

whose construction was completed last year. Aim to improve profitability by strengthening business

foundation (e.g., stable operations at the Miyazaki Factory and cost optimization through integration of

bases).


16%

12%

31%3%

12%

8%

19%

14

FY2018 Q3Jan.2018 – Sep. 2018

FY2019 Q3Jan. 2019 – Sep. 2019

YoY comparison

Change Change rate

Orders 42,747 46,387 +3,640 +8.5％

Revenue 42,734 45,719 ＋2,984 ＋7.0％

FY2019Q3


Medical Division


Millions of JPY(Japan) Dialysis machines

(Overseas) Dialysis machines

(Japan) Disposable

(Overseas) Disposable

Maintenance

CRRT

Others

1. Overview

✓ Sales of new hemodialysis machines that were domestically launched in the 2nd half were strong,

and those of disposables also remained solid as a whole.

✓ As the sales of hemodialysis machines in the European market also continued to be strong, the

hemodialysis business increased its revenue and profit as a whole on a year-on-year basis.

✓ The Medical Business saw its revenue increase but its profit decrease year on year as a whole as it

posted asset impairment losses (i.e. recoverable amount is less than the book value) as a result of

worsened performance of the CRRT (Continuous Renal Replacement Therapy) business.

Ⅲ. Financial forecast


FY2018Actual record

FY2019Previous Forecast

FY2019RevisedForecast

Y on Y

comparison

Comparison with

previous forecast

Change Change rate Change

Orders 172,492 171,500 171,500 △992 △0.6% 0

Revenue 165,326 170,000 170,000 +4,673 +2.8% 0

Operating profit 10,302 12,000 12,000 +1,697 +16.5% 0

Operating margin 6.2% 7.1% 7.1%

Profit before tax 9,741 11,200 11,200 +1,458 +15.0% 0

Pretax profit margin 5.9% 6.6% 6.6%

attributable to owners of the company

Profit for the year 7,448 8,200 6,700 △748 △10.1% △1,500

Profit margin attributable to owners of the company

4.5% 4.8% 3.9%

Average/ForecastAgainst the US dollar (Yen)

Against the euro (Yen)110.44130.35

109.00122.00

109.00122.00

△1.44△8.35

0.000.00

Forex sensitivity for FY2019 (When

yen was depreciated by 1 yen)

US dollar (Yen)

Euro (Yen)

Revenue +430 million yen Operating profit +80 million yen

Revenue +370 million yen Operating profit +60 million yen

Financial forecast for FY2019

Consolidated Performance

Millions of JPY

Revision of profit for the year attributable to owners of the company.(8.2 billion yen→6.7 billion yen）


FY2018Actual record

FY2019Previous Forecast

FY2019RevisedForecast

Y on Y comparison

Comparison with

Previous forecast

Industrial Business

Orders 111,459 107,200 107,200 △4,259 0

Revenue 104,501 105,700 105,700 +1,198 0

Operating profit 8,140 8,000 10,0009.5%

+1,859 +2,000


Industrial DivisionOrders 82,238 79,900 79,900 △2,338 0

Revenue 76,763 77,900 77,900 +1,136 0

Precision Equipment

Division

Orders 12,204 9,200 9,200 △3,004 0

Revenue 10,682 9,700 9,700 △982 0

Aerospace DivisionOrders 16,884 17,600 17,600 +715 0

Revenue 16,909 17,600 17,600 +690 0

Medical Business

Orders 61,032 64,300 64,300 +3,267 0

Revenue 60,824 64,300 64,300 +3,475 0

Operating profit 5,582 6,000 4,0006.2%

△1,582 △2,000


Corporate expenses, etc. Operating profit △3,419 △2,000 △2,000 +1,419 0


Performance by Business Segment

Millions of JPY

Revision of operating profit forecast.(Industrial:8 billion yen→10 billion yen Medical:6 billion yen→4 billion yen)


1. Revision of profit for the year attributable to owners of the company


Supplementary explanation concerning the revised performance forecasts

✓ Revised profit for the year attributable to owners of the company as the effective tax rate was

pushed up due to the posting of impairment losses, etc. related to the CRRT business in the 3rd

quarter under review and the estimated tax rate used for performance forecasts was revised based

on the actual tax rate for the fiscal year under review. (8.2 billion yen→6.7 billion yen）

２.Revision of operating profit

✓ Revised the Industrial Division’s operating profit due to the posting of income from licensing

and providing development services in connection with the deep UV-LED business.

(8 billion yen→10 billion yen）

✓ Revised the Medical Division’s operating profit due to the posting of impairment losses

related to CRRT (Continuous Renal Replacement Therapy) business assets.

(6 billion yen→4 billion yen）

✓ No change in the Company’s operating profit.(12 billion yen)

Appendix


< Medical >< Aerospace >< Industrial and Precision

Equipment, etc. >

20

Orders Analysis (vs FY2018 Q3)

Millions of JPY

FY2019 Q3(Jan.2019-Sep.2019)

Orders

126,325FY2018 Q3

(Jan.2018-Sep.2018)Orders

122,745

Simpleincrease Impact of FX

＋4,265 △625

＋715

Simpleincrease

△2,128

Impact of FX

Impact of FX

+1,340 +11

Simpleincrease

Overseas subsidiaries in the Industrial

Business received more orders, but

this was offset by fewer orders for

precision equipment. Posting of UV-

LED development service revenue.

✓ LEWA received increasingly

more orders, but was affected

negatively by the euro’s

appreciation.

✓ Orders for large LNG cryogenic

pumps increased.

✓ Regarding precision equipment,

particle analytical equipment

business is excluded from

consolidation. Orders

decreased due to poor

electronic component-related

business performance.

✓ Orders for cascades increased.

✓ Orders for fan case liners

increased.

✓ Steady sales of new

hemodialysis machines in

Japan.

✓ Strong sales of disposables

such as blood tubing lines

and powder dialysate.

✓ Strong sales of hemodialysis

machines in Europe.


< Medical>< Aerospace >< Industrial and Precision Equipment, etc. >

21

Revenue Analysis (vs FY2018 Q3)

Millions of JPY

Simpleincrease Impact of FX

FY2018 Q3(Jan.2018-Sep.2018)

Revenue

115,437

△624＋3,608

Simpleincrease

＋3,347 △1,904

Impact of FX Simpleincrease

＋1,316

Impact of FX

＋11

FY2019 Q3(Jan.2019-Sep.2019)

Revenue

121,193

✓ Sales of cascades increased.

✓ Sales of fan case liners

increased.

✓ Steady sales of new

hemodialysis machines in

Japan.

✓ Strong sales of disposables

such as blood tubing lines

and powder dialysate.

✓ Strong sales of hemodialysis

machines in Europe.

Industrial Business sales increased.

Regarding precision equipment,

shipments for existing electronic

component-related orders

increased. UV-LED development

service revenue was generated.

✓ Sales of LEWA and the CI Group

increased.


< Medical>< Aerospace >< Industrial and Precision

Equipment, etc. >

22

Operating profit Analysis (vs FY2018 Q3)

Millions of JPY

increase incorporate

expenses, etc.

Impact of FX△1,307

△158

+2,313

FY2018 Q3

(Jan.2018-Sep.2018)

Operating profit

6,308

Simpledecrease

△295△199

Impact of FX

+2,851

Simpleincrease

＋0

Impact of FX

FY2019 Q3

(Jan.2019-Sep.2019）

Operating profit

9,511Simple

decrease

✓ Impairment losses related to

CRRT (Continuous Renal

Replacement Therapy)

business assets

✓ Increased sales of

hemodialysis machines, blood

tubing lines and powder

dialysate mainly in Japan.

✓ The Miyazaki Factory’s

depreciation and other

expenses increased.

✓ Gains on sales of

shares in the

particle analytical

equipment

business, etc.

Higher sales of overseas

subsidiaries in the Industrial

Business. Regarding precision

equipment, shipments for

existing electronic component-

related orders increased. UV-

LED licensing income, etc.

✓ LEWA’s sales increased.

✓ The CI Group achieved

strong sales and decreased

its depreciation expenses.


As of end of December 2018 As of end of September 2019

AmountComposition

ratio AmountComposition

ratio Change

Total assets 249,788 100.0％ 261,603 100.0% +11,814

Total current assets 121,342 48.6% 122,447 46.8% +1,104

Cash and cash equivalents 29,269 11.7% 31,403 12.0% +2,133

Trade and other receivables 54,077 21.6% 51,154 19.6% △2,922

Inventories 33,297 13.3% 35,592 13.6% ＋2,294

Total non-current assets 128,446 51.4% 139,156 53.2% ＋10,709

Property, plant and equipment 44,920 18.0% 41,943 16.0% △2,977

Goodwill and Intangible assets 64,255 25.7% 62,287 23.8% △1,968

Total liabilities 171,450 68.6% 183,769 70.2% ＋12,319

Trade and other payables 27,380 11.0% 26,625 10.2% △754

Bonds and borrowings 117,052 46.9% 116,978 44.7% △74

Total equity 78,338 31.4% 77,833 29.8% △504

Consolidated Statement of Financial Position

Millions of JPY

※Assets and Liabilities as of September 30, 2019, were increased compared to the end of the previous fiscal year, due mainly to an increase in right-of-use

assets and lease liabilities resulting from the application of IFRS 16.


Japan

37%

Asia24%

North America

18%

Europe18%

Others3%

24

MedicalAerospacePrecision Equipment

62%

29%

4%3%1% 日本

アジア

北米

欧州

その他

18%

6%

72%

4%

71%

14%

1%12%

2%

20%

30%

40%

50%

60%

70%

0

20,000

40,000

60,000

80,000

100,000

120,000

08/3 09/3 10/3 11/3 12/3 13/3 14/3 15/3 15/12 16/12 17/12 18/12

アジア北米

欧州その他

海外売上収益比率（右軸）

FY2019 Q3

Nikkiso group total Revenue trend by overseas region

FY2019 Q3

FY2019 Q3

Overseas revenue ratio

63%

(9 months)

Industrial

11%

35%

20%

30%

4%

FY2019 Q3

FY2019 Q3

Revenue Composition Ratio by Region

Millions of JPYAsia North America

Europe Other

Overseas revenue ratio (right axis)

Japan

Asia

North America

Europe

Other


FY2019

Performance forecast

Against the US dollar Against the euro

RevenueOperating

profitRevenue

Operating

profit

Industrial Division/

Precision Equipment

Division+290 +20 +300 +30

Aerospace Division +140 +80 +0 +0

Medical Division +10 △30 +70 +30

Total +430 +80 +370 +60

Average/Forecast (Yen） 109.00 122.00

Breakdown of forex sensitivity

※When yen was depreciated by 1 yen

Millions of JPY


FY2016 FY2017 FY2018

Earnings per share (Basic) 66.08yen 72.82yen 104.63yen

Return on equity (ROE) 7.2% 7.3% 9.8%

Return on asset (ROA) 3.8% 3.9% 3.9%

Operating margin 6.2% 6.2% 6.2%

Equity ratio 37.4% 30.7% 30.7%

Debt/equity ratio 1.05times 1.63times 1.53times

FY2016 FY2017 FY2018

Capital expenditure 7,635 7,508 12,869

Research and development expenditure 1,679 2,435 2,387

Depreciation and amortization 4,766 5,246 6,335

Financial data

Millions of JPY


27

Quarterly orders/order backlog trend of Industrial Division

Orders

Order backlog

Millions of JPY

1st Quarter 2nd Quarter 3rd Quarter 4th Quarter

FY201711,261 14,331 14,132 19,103

overseas 9,487 12,241 12,425 17,113

FY201820,066 19,760 18,808 23,604

overseas 18,316 17,659 16,974 20,488

FY201921,676 19,727 18,147

overseas 20,422 16,050 17,186


FY201729,727 30,582 39,461 38,198

overseas 26,570 27,174 36,036 34,834

FY201843,058 44,457 43,496 43,674

overseas 40,088 41,298 40,305 39,608

FY201947,813 49,402 48,938

overseas 44,435 44,282 44,900

27


Quarterly revenue trend

Millions of JPY


Industrial Division

FY201710,522 13,476 15,274 20,443

overseas 8,321 12,502 13,393 16,986

FY201815,206 18,361 19,770 23,426

overseas 13,247 16,289 17,809 21,203

FY201917,536 18,138 18,610

overseas 15,595 16,203 16,567


FY20172,421 2,377 2,070 2,975

overseas 745 885 821 775

FY20182,516 2,640 2,187 3,339

overseas 604 794 739 1,177

FY20192,518 2,947 1,589

overseas 896 1,113 662

Aerospace Division

FY20173,578 3,991 3,779 4,202

overseas 2,920 3,606 3,306 3,865

FY20183,792 4,213 3,924 4,980

overseas 3,301 3,648 3,114 4,240

FY20194,168 4,431 4,656

overseas 3,389 3,704 3,803

Medical Division

FY201712,964 13,521 13,114 16,085

overseas 3,834 3,959 4,623 3,671

FY201812,936 15,855 13,943 18,090

overseas 4,148 4,586 4,682 5,335

FY201913,175 15,861 16,681

overseas 4,193 4,703 4,420

Company Information


130.0

140.9

165.3

8.1

8.7

10.3

0.0

150.0

16/12 17/12 18/12

Industrial business 63%

Medical business

37%

Industrial Division

47%Medical Division

37%

Aerospace Division

10%

FY2018


6%

72.3 78.0

83.1 90.1

103.6

121.5 129.2

110.2

132.8

4.7

5.6 5.3

6.5

7.4

9.4

6.1

3.8

4.8

0.0

150.0

09/3 10/3 11/3 12/3 13/3 14/3 15/3 15/12 16/12

Net sales Operating income

JGAAP IFRS

Revenue Operating Profit

( billion yen )

Trend in Revenue/Operating Profit

Consolidated Revenue

Revenue by Segment


(IFRS)(IFRS)(IFRS)(9months)

Acquired the LEWA Group Acquired Geveke B.V. Higashimurayama Aerospace factory

Acquired the Cryogenic Industries group

33,663

43,076

52,393 54,663

69,307

79,239

69,536 75,183

85,406

111,459 107,300

37,233

42,123

47,490

55,176

68,588

74,960

68,625

75,593

85,228

104,501 105,700

3,444 2,760 4,662 3,770 5,102 4,375 3,668

5,932 7,539 8,140 10,000

0.0%

2.0%

4.0%

6.0%

8.0%

10.0%

12.0%

14.0%

16.0%

18.0%

20.0%

0

20,000

40,000

60,000

80,000

100,000

120,000

2010/03 2011/03 2012/03 2013/03 2014/03 2015/03 2015/12 2016/12 2017/12 2018/12 2019/12

受注高売上収益セグメント利益セグメント利益率

Aerospace product expansion

Transferred production from Shizuoka to Kanazawa

(revised forecast)

Performance trend of Industrial Business

Millions of JPYOrder (Left axis) Revenue (Left axis) Operating profit (Left axis) Operating margin (Right axis)


136132

195 194 204

220236 232

200

247

127 129

148

189

217 217224 219

236 237

14 13 1727 30 31 28

21 28 22

0

20

40

60

80

100

120

0

50

100

150

200

250

300

09 10 11 12 13 14 15 16 17 18

受注高（左軸）売上収益（左軸） EBITDA（左軸）原油価格（右軸）

36%

41%

23%

FY2010

（Source）Crude oil price：The World Bank Group「Commodity Markets Outlook」

34%

36%

6%

24%

FY2015

25%

38%

10%

28%

FY2018

32

Performance trend of LEWA

Oil & Gas

Process industry

Clean market

After service

Revenue Composition ratio

Millions of € ＄/barrel

Order (Left axis) Revenue (Left axis) EBITDA (Left axis) Crude oil price (Right axis)


Full-scale sales of DCS-100NX,

a multipurpose dialysis

monitoring device (from

January 2012)

Sales of DBB-EXA, a dialysis device for personal use

(in overseas markets) (from 2015)

Consumption tax hike in April 2014 (to 8% from 5%)

(IFRS) (IFRS) (IFRS)

Acquired the CRRT business

Transferred production from Shizuoka to Kanazawa

Higher demand for online HDF

40,786 41,019 42,646

48,493

52,960 54,295

41,592

54,451 55,684

60,824

64,300

5,226 5,598 5,224 6,962 7,845

5,243 3,041

5,209 3,950

5,582 4,000

0.0%

2.0%

4.0%

6.0%

8.0%

10.0%

12.0%

14.0%

16.0%

18.0%

20.0%

0

10,000

20,000

30,000

40,000

50,000

60,000

70,000

2010/03 2011/03 2012/03 2013/03 2014/03 03/2015 2015/12 2016/12 2017/12 2018/12 2019/12

売上収益セグメント利益セグメント利益率

Performance trend of Medical Business

(9months)

Millions of JPY

Revenue (Left axis) Operating profit (Left axis) Operating margin (Right axis)

(revised forecast)


Medical Division

Aerospace Division

Industrial Division

69 71 74 75 83 87 95 01 09 1053 54 56 60 61 67 1285 13 15 1714 18

Footsteps of the NIKKISO Group

History

Company is established for the purpose of import and sales of reciprocating metering pumps.

Develops a water conditioning system for power plants and begins production and sales of systems.

Introduces Japan’s first leak-free canned motor pump technology and begins production and sales of pumps.

Begins import and sales of artificial dialysis machines for the first time in Japan.

Completes Japan’s first hemodialysis machine and begins production and sales of machines.

Begins production and sales of dialyzers for hemodialysis.

Begins production and sales of cascades made of carbon fiber reinforced plastic as components for commercial aircraft.

Obtains a license for the technology to manufacture Microtrac particle size analyzers from Honeywell Inc. of the U.S.

Acquires CRRT business of Baxter International Inc.

Begins production of bloodtubing lines for hemodialysisin Vietnam.

Completes construction of Higashimurayama Plant.

Listing on the second section of the Tokyo Stock Exchange.

Listing on the first section of the Tokyo Stock Exchange.

Completes construction of Shizuoka Plant.

Begins manufacturing andsales of cryogenic pumps.

Completes construction ofKanazawa Plant.

Acquires the LEWA Group of Germany.

Accepts transfer of a German Fresenius Medical Care’s dialyzer and peritoneal dialysis product selling in Japan.

Establishes a joint venture with the China-based Weigaofor the manufacture and maintenance of dialysis machine

Decides to transfer the production function from Shizuoka Plant to Kanazawa Plant as part of the anti-disaster measure.

Acquires Geveke B.V. of the Netherland

Acquires Cryogenic pump business of Atlas Copco.

Acquires the Cryogenic Industries Group of U.S.A.

Completes construction ofAerospace factory at theMiyazaki Nikkiso

Documents

Financial results for FY2019 Q3 Financial Summary...2019/11/14 · Q3 FY2018 Q3 Jan.2018 –Sep. 2018 FY2019 Q3 Jan. 2019 –Sep 2019 YoY comparison Change Change rate Orders 9,368